Boston Children's Hospital spinout Claritas Genomics, a genetic diagnostic testing company, attracted an investment from IT specialist Cerner, and the two will collaborate to develop a computing infrastructure designed to smooth the diagnostic process from start to finish.
Switzerland's Biocartis will link up with Belgium's VIB research institute to develop a diagnostic test useful for colorectal and other cancers, the company said.
Well-traveled biotech luminary Michael Foley has agreed to head up a new translational research effort that unites minds at Weill Cornell Medical College, the Rockefeller University and Memorial Sloan-Kettering Cancer Center with the mission of turning exciting lab work into promising drug candidates.
GlaxoSmithKline is launching what it calls the Oncology Clinical and Translational Consortium, a collaborative scientific research network intended to advance drug discovery that will include 6 cancer centers around the world.
Stem cell technology developer Cellular Dynamics said Wednesday it will collaborate with the nonprofit Jain Foundation to create induced pluripotent stem cell lines from patients with certain genetic muscular dystrophies in an effort to find stem cell-based therapies for these disorders.
Unilife is at it again. This time it's Novartis signing a deal with the injectable technology provider, adding to Unilife's impressive list of recent agreements with top pharmaceutical companies Sanofi, MedImmune and Hikma.
A little more than two months after GlaxoSmithKline abandoned its $1.5 billion partnership on ChemoCentryx's lead drug, the Crohn's drug vercirnon, scrapping three late-stage studies after the first Phase III flopped, the biotech says that GSK has begged off pursuing a follow-up anti-inflammatory program and returned another drug--CCX354--licensed out four years ago.
Switzerland's Molecular Partners is convinced that it has created a better delivery vehicle for cancer drugs, and Roche is promising to pay up to a billion dollars-plus to see if they're right.
Celgene helped seal its reputation as one of the boldest dealmakers in biotech today, putting up $177.25 million in an upfront fee and equity stake while committing to more than $3 billion in milestones to partner on a slate of cancer stem cell programs in development at OncoMed.
The transactional model that once accounted for all CRO business is rapidly losing steam, Parexel International tells Outsourcing-Pharma, as Big Pharma sponsors recognize the benefits of deeper-seated strategic partnerships